THE POTENTIAL OF CANNABIS FOR MEDICAL PURPOSES

It is known that 40-60% of the medicines on the world market come from plant extracts, including some of the most recent chemotherapy drugs such as taxanes. Like any medication, the use of cannabinoids should be done in areas that are studied and recognized. Their undeniable potential to replace other drugs with significant side effects should favor the introduction of medical derivatives of cannabis into the therapeutic arsenal of clinicians, for the benefit of patients. Despite the convincing medical literature, the proven therapeutic benefits of cannabinoids are still greatly underestimated and underutilized in the general and medical population.

Like all mammals, humans produce endogenous cannabinoids (endocannabinoids) that share similarities with cannabinoids from the plant (phytocannabinoids). The human body therefore already has type 1 or 2 receptors (CB1, CB2) to which the cannabinoids bind. Of these, THC (Tetrahydrocannabinol) and CBD (Cannabidiol) are among the most commonly measured for medical purposes.

A receptor is like a keyhole, in which a specific molecule (here THC or CBD) is introduced as a key would do, and can deliver its therapeutic effect. A similar model: the opiate receptors of the human body, with molecules such as morphine that binds to it to give its therapeutic effect.

Les récepteurs CB1 sont principalement retrouvés dans le système nerveux central et périphérique (cerveau et nerfs), alors que les récepteurs CB2 le sont situés dans le système immunitaire. D’autres voies d’activation existent également.

The measurement of the different concentrations of each cannabinoid is therefore essential and must be evaluated very precisely, as well as being replicable.

The legalization of medical cannabis production in Canada also allows for more rigorous scientific research into cannabinoids to identify the most active therapeutic molecules and their best routes of administration. As with any well-recognized medication, patients and clinicians have the right to expect the highest quality available and continuous availability of therapeutic products.